Syndax Pharmaceuticals has delivered a 63.5% gain over the past year, yet the broader valuation checks and current market multiples suggest the stock is not an obvious bargain at today’s price of US$20.40.

• The 63.5% one year return points to strong recent optimism already reflected in Syndax Pharmaceuticals' share price.
• Progress on its oncology pipeline and upcoming clinical data can support expectations for future revenue, while the execution and clinical risks around those same programs may limit how much investors are willing to pay up today.
• With a value score of 4 out of 6, Syndax Pharmaceuticals presents a mixed picture rather than a clear bargain or clear overvaluation on the standard checks.

The issue now is whether the current US$20.40 share price already reflects the recent strength in Syndax Pharmaceuticals, or if the stock still offers room for valuation upside.

Is Syndax Pharmaceuticals Getting Expensive on Sales?

The P/S ratio is often a cleaner benchmark for a company like Syndax Pharmaceuticals, where earnings are not yet a reliable guide. At the current share price, Syndax trades on a P/S of 7.2x, which sits below the broader biotech industry average of 11.4x and also below a peer average of 15.9x.

The tailored fair P/S ratio for Syndax Pharmaceuticals, which blends its sector, size, growth profile and risk into a single benchmark, comes out at 3.4x. That is roughly half of where the stock trades today. Despite the recent Q2 2026 update on expanded commercial products and pipeline progress, the current P/S still embeds a premium to this fair ratio. This suggests investors are already pricing in a lot of optimism about future sales.

On the P/S multiple, Syndax Pharmaceuticals stock screens as overvalued relative to the level that would typically be justified by its fundamentals and risk profile.

The Syndax Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Syndax Pharmaceuticals pick up where the valuation puzzle leaves off and explain which growth, margin and earnings paths would need to occur for the stock to appear meaningfully cheaper or more expensive than it does today. Each narrative links its figures to a clear view on how Syndax Pharmaceuticals' growth, profitability and risks might develop, which you can revisit on the Community page as new clinical or financial data becomes available.

One of the top community narratives on Syndax Pharmaceuticals: 22% undervalued

"The company's financial performance is heavily dependent on a limited product pipeline, with only two primary drugs in commercial stages. Any setbacks such as FDA delays, negative real-world safety or efficacy outcomes, or less-than-expected label expansions could sharply curtail future revenue, earnings, and margin growth..."

Do you think there's more to the story for Syndax Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Syndax Pharmaceuticals screens as overvalued on current sales multiples, even after accounting for its sector, size and risk profile. The mixed value score reinforces that this is not a clear-cut bargain, yet also not an obvious excess where the story no longer matters. What really determines the outcome from here is whether the oncology pipeline can translate into revenue that eventually aligns with the valuation premium investors are already paying. The central question is whether that optimism proves justified or whether the stock needs a reset if clinical or commercial progress falls short.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.